Helix Biopharma Corp. Announces Conclusion of Funding Agreement with Lind Global Macro Fund LP

(Toronto, Ontario) – Helix BioPharma Corp. (TSX: “HBP”) (“Helix” or the “Company”), a clinical-stage biopharmaceutical company that is developing unique therapies in the field of immuno-oncology based on its proprietary technology platform DOS47, is pleased to announce that it has completed the buyback of the outstanding amount of the convertible security funding agreement (the “Agreement”) with Lind Global Macro Fund, LP, a New York based institutional investment fund managed by The Lind Partners, LLC (together, “Lind”).

 

Helix Aug 30 PR